The research activity of GRIB has originated the creation of the following spin-off companies:
* BioCloud Services founded in 2015 with the participation of Alba Gutiérrez-Sacristan, researcher of the IBI Group of GRIB as Chief Science Officer (CSO).
BioCloud aims to provide cloud solutions for bioinformatic challenges such as the lack of computational power, lack of reproducibility of data analysis or data sharing difficulties among others. The startup also provides teaching tools for university courses and workshops when high computational power or data storage is needed. Currently Biocloud has started by providing support at Master of Omic Data Analysis (UVIc) and Master of Bioinformatics (UAB).
Chemotargets core in silico pharmacology platform currently allows for predicting the affinity profile of small molecules on 4,790 targets, that include members of the main protein families of therapeutical relevance, namely, enzymes (2,308), GPCRs (225), transporters/ion channels (357), and nuclear receptors (34). In addition, a new approach to anticipate the side-effect profile of drugs has been recently developed and it is currently being applied in EU projects in collaboration with the pharmaceutical industry. This platform is being exploited through collaboration agreements with drug discovery and chemical partners.
Acellera is a technology company focused on delivering services and solutions to companies and academic institutions on computing intensive, mission-critical applications. By exploiting heavily optimized molecular simulations and the outstanding computational capabilities of new accelerator processors, we help to achieve otherwise unreachable results using current standard technology.
* Pharmatools Interactive Services, founded by Ferran Sanz, head of the Integrative Biomedical Informatics group.